ImmunoCobiVem

The phase II ImmunoCobiVem trial evaluated whether a short run-in with targeted therapy followed by a switch to immunotherapy before progression improves outcomes in patients with BRAF-mutant advanced melanoma. In this video, Prof Dr Jeroen Mebis (Jessa Hospital, Hasselt, Belgium) shares the long-term results of this trial presented at ESMO 2024.

In this trial, patients with BRAFV600-mutant unresectable or metastatic melanoma were initially treated with 3 months of vemurafenib + cobimetinib after which patients were randomized between continued targeted therapy until disease progression followed by a switch to atezolizumab (Arm A), or an immediate switch to atezolizumab with a subsequent cross-over to vemurafenib + cobimetinib at progression. (Arm B). Updated results of this trial show a non-significant trend for a better OS in Arm B, with a median OS of 49.6 months as compared to 40.2 months in Arm A (5-year OS rates 40% in Arm A vs. 45% in Arm B, HR[95%CI]: 1.17[0.71-1.91]). Importantly, however, a relevant proportion of patients did experience a rapid progression after the early switch from targeted therapy to atezolizumab.